Welcome to JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) May 16, 2025
LIAO Wen-sheng, SHAO Yan-xiang, SUN Guang-xi, et al. Application of Prognostic Predication Model in Clinical Non-metastatic Renal Cell Carcinoma[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(5): 720-724.
Citation: LIAO Wen-sheng, SHAO Yan-xiang, SUN Guang-xi, et al. Application of Prognostic Predication Model in Clinical Non-metastatic Renal Cell Carcinoma[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(5): 720-724.

Application of Prognostic Predication Model in Clinical Non-metastatic Renal Cell Carcinoma

More Information
  • Corresponding author:

    LI Xiang, E-mail: xiangli.87@163.com

  • Received Date: February 11, 2019
  • Revised Date: July 02, 2019
  • Available Online: March 16, 2021
  • Published Date: September 19, 2019
  •   Objective   To study and compare the practical use of three prognostic predication models in clinical non-metastatic renal cell carcinoma (RCC).
      Methods   We retrospectively collected the data of 1 202 clinical non-metastatic RCC patients operated on between 1999 and 2012 at West China Hospital of Sichuan University. Survival analysis method was used to establish three prognostic prediction models including SSIGN, Leibovich and UISS based on different clinical and pathological indicators. The predictive ability was evaluated by the area under receiver operating characteristic curve (AUC).
      Results   Of the 1 202 clinical non-metastatic RCC patients, 1 030 cases were limited RCC patients, and 172 cases were locally advanced RCC patients. The median follow-up time of the patients was 63.02 months. The 2-year and 5-year overall survival rate were 94.7% and 87.6%, respectively. The 5-year overall survival rates of patients with different clinical stages and grades were significantly different. The predictive accuracies for limited RCC of UISS, SSIGN and Leibovich model were 0.667, 0.785 and 0.758, respectively. For locally advanced RCC, the predictive accuracies of the three models were all lower than 0.6.
      Conclusion   SSIGN has certain predictive value in clinical non-metastatic RCC. However, for the advanced RCC, all the prognostic models demonstrate limited predictive value.
  • [1]
    ALAN J W, LOUIS R K, AKAN W P, CRAIG A P. Campbell-Walsh.Urology, 11th, 2016. ELSEVIER, USA, 2016. https://www.abe.pl/en/default/error/error
    [2]
    CHOW W H, DEVESA S S.Contemporary epidemiology of renal cell cancer. Cancer J, 2008, 14(5):288-301. DOI: 10.1097/PPO.0b013e3181867628
    [3]
    ZISMAN A, PANTUCK A J, DOREY F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol, 2002, 20:1368-1374. DOI: 10.1200/JCO.2002.20.5.1368
    [4]
    ZISMAN A, PANTUCK A J, DOREY F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 2001, 19(6):1649-1657. DOI: 10.1200/JCO.2001.19.6.1649
    [5]
    LEIBOVICH B C, BLUTE M L, CHEVILLE J C, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma:a stratification tool for prospective clinical trials. Cancer, 2003, 97(7):1663-1671. DOI: 10.1002/cncr.11234
    [6]
    FRANK I, BLUTE M L, CHEVILLE J C, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis:the SSIGN score. J Urol, 2002, 168(6):2395-2400. DOI: 10.1016/S0022-5347(05)64153-5
    [7]
    ROY-CHAUDHURY P, ARNOLD P, SEIGEL J, et al. From basic biology to randomized clinical trial:the Beta Radiation for Arteriovenous Graft Outflow Stenosis (BRAVO Ⅱ). Semin Dial, 2013, 26(2):227-232. DOI: 10.1111/sdi.12000
    [8]
    KARAKIEWICZ P I, BRIGANTI A, CHUN F K, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol, 2007, 25(11):1316-1322. DOI: 10.1200/JCO.2006.06.1218
    [9]
    ZIGEUNER R, HUTTERER G, CHROMECKI T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol, 2010, 57(1):102-109. DOI: 10.1016/j.eururo.2008.11.033
    [10]
    CINDOLO L, CHIODINI P, GALLO C, et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer, 2008, 113(1):65-71. DOI: 10.1002/cncr.23517
    [11]
    CINDOLO L, PATARD J J, CHIODINI P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy:a multicenter European study. Cancer, 2005, 104(7):1362-1371. DOI: 10.1002/cncr.21331
    [12]
    FICARRA V, NOVARA G, GALFANO A, et al. The stage, size, grade and necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int, 2009, 103(2):165-170. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_JJ027394503
    [13]
    HADDAD H, RINI B I. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol, 2012, 13(2):212-229. DOI: 10.1007/s11864-012-0182-8
    [14]
    LIU Z, LV J, DING K, et al. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population:a 15-year single center experience. Int J Urol, 2009, 16(3):268-273. DOI: 10.1111/j.1442-2042.2008.02229.x
    [15]
    PARKER W P, CHEVILLE J C, FRANK I, et al. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol, 2017, 71(4):665-673. DOI: 10.1016/j.eururo.2016.05.034
    [16]
    FUJⅡ Y, SAITO K, ⅡMURA Y, et al. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol, 2008, 180(4):1290-1295. DOI: 10.1016/j.juro.2008.06.014
    [17]
    BEISLAND C, GUDBRANDSDOTTIR G, REISAETER L A, et al. Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. Scand J Urol, 2015, 49(3):205-210. DOI: 10.3109/21681805.2014.980844
    [18]
    PICHLER M, HUTTERER G C, CHROMECKI T F, et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol, 2011, 186(5):1773-1777. DOI: 10.1016/j.juro.2011.07.034
    [19]
    TAN M H, KANESVARAN R, LI H, et al. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology, 2010, 75(5):1365-1370. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM20022084
    [20]
    TAN M H, LI H, CHOONG C V, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer, 2011, 117(23):5314-5324. DOI: 10.1002/cncr.26193

Catalog

    Article views (3129) PDF downloads (62) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return